List of investigational antidepressants

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

This is a list of investigational antidepressants, or antidepressants that are currently under development for clinical use in the treatment of mood disorders but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. All drugs listed are specifically under development for major depressive disorder (MDD) or treatment-resistant depression (TRD) unless noted otherwise.

Glutamatergics[edit]

NMDA receptor modulators[edit]

Others[edit]

Monoaminergics[edit]

Monoamine reuptake inhibitors[edit]

Monoamine reuptake inhibitors and receptor modulators[edit]

Monoamine receptor modulators[edit]

  • Gepirone (TGFK07AD; Travivo) – 5-HT1A receptor partial agonist[20]
  • Pimavanserin (Nuplazid; ACP-103; BVF-048) – 5-HT2A receptor antagonist[21]

Atypical antipsychotics[edit]

Others[edit]

Neurosteroids[edit]

GABAA receptor positive modulators[edit]

Others[edit]

Opioidergics[edit]

κ-Opioid receptor antagonists[edit]

Others[edit]

Others[edit]

Mixed[edit]

Combinations[edit]

Not under development[edit]

The following drugs are currently of major investigational interest as potential antidepressants but are not formally under clinical development for approval at this time:

See also[edit]

References[edit]

  1. ^ "AV 101 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  2. ^ "Research programme: NMDA receptor modulators - Allergan - AdisInsight". adisinsight.springer.com. Retrieved 28 August 2018. 
  3. ^ "Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration". www.prnewswire.com. Retrieved 28 August 2018. 
  4. ^ "Apimostinel - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  5. ^ "Esketamine - Johnson & Johnson - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  6. ^ "EVT 101 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  7. ^ "EVT 103 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  8. ^ "Ketamine intranasal - Vyera Pharmaceuticals - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  9. ^ "Rapastinel - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  10. ^ "CERC 301 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  11. ^ "Basimglurant - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  12. ^ Machado-Vieira R, Henter ID, Zarate CA (2017). "New targets for rapid antidepressant action". Prog. Neurobiol. 152: 21–37. doi:10.1016/j.pneurobio.2015.12.001. PMID 26724279. 
  13. ^ a b Lener MS, Kadriu B, Zarate CA (2017). "Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression". Drugs. 77 (4): 381–401. doi:10.1007/s40265-017-0702-8. PMID 28194724. 
  14. ^ "Tulrampator - AdisInsight". adisinsight.springer.com. Retrieved 31 May 2017. 
  15. ^ "AN 788 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  16. ^ "LY 03005 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  17. ^ "PDC-1421 - AdisInsight". adisinsight.springer.com. Retrieved 24 March 2018. 
  18. ^ "MIN 117 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  19. ^ "FKB 01MD - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  20. ^ "Gepirone ER - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  21. ^ "Pimavanserin - AdisInsight". adisinsight.springer.com. Retrieved 25 September 2017. 
  22. ^ "Aripiprazole/sertraline - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  23. ^ "Cariprazine - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  24. ^ "Lumateperone - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  25. ^ "Lurasidone - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  26. ^ "RP 5063 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  27. ^ "Ademetionine - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  28. ^ "Brexanolone - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  29. ^ "Ganaxolone - AdisInsight". adisinsight.springer.com. Retrieved 24 March 2018. 
  30. ^ "SAGE 217 - AdisInsight". adisinsight.springer.com. Retrieved 9 February 2018. 
  31. ^ "Pregnenolone methyl ether - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  32. ^ "PH 10 nasal spray - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  33. ^ "Buprenorphine/samidorphan - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  34. ^ "CERC 501 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  35. ^ "BTRX-246040 - AdisInsight". adisinsight.springer.com. Retrieved 24 March 2018. 
  36. ^ "JNJ 39393406 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  37. ^ "JNJ-54175446 - AdisInsight". adisinsight.springer.com. Retrieved 24 March 2018. 
  38. ^ "Research programme: psychiatric and neurological disorders therapeutics - Neuronascent - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  39. ^ "NSI 189 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  40. ^ Duman RS (2018). "Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide". F1000Res. 7. doi:10.12688/f1000research.14344.1. PMC 5968361Freely accessible. PMID 29899972. 
  41. ^ Duman, R., Kato, T., Liu, R. J., Duman, C., Terwilliger, R., Vlasuk, G., ... & Sajah, E. (2017, November). Sestrin 2 Modulator NV-5138 Shows Ketamine-Like Rapid Antidepressant Effects via Direct Activation of mTORC1 Signaling. In Neuropsychopharmacology (Vol. 43, pp. S195-S195). Macmillan Building, 4 Crinan St, London N1 9Xw, England: Nature Publishing Group. https://www.nature.com/articles/npp2017264.pdf
  42. ^ "Botulinum toxin A injectable - Allergan - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  43. ^ "JNJ 42847922 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  44. ^ "Sirukumab - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  45. ^ "SUVN-911 - AdisInsight". adisinsight.springer.com. Retrieved 24 March 2018. 
  46. ^ "TS 121 - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  47. ^ "Tramadol controlled release - e-Therapeutics - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  48. ^ "Another depression drug flops as e-Therapeutics tallies PhIIb data - FierceBiotech". www.fiercebiotech.com. Retrieved 28 August 2018. 
  49. ^ "E-Therapeutics defends PhIIb fail, claiming drug has 'pretty much' the hoped-for profile - FierceBiotech". www.fiercebiotech.com. Retrieved 28 August 2018. 
  50. ^ "Bupropion/dextromethorphan - Axsome Therapeutics - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  51. ^ "Cycloserine/lurasidone - NeuroRx - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  52. ^ "Deudextromethorphan - AdisInsight". adisinsight.springer.com. Retrieved 7 May 2017. 
  53. ^ Zeng Y, Wang X, Wang Q, Liu S, Hu X, McClintock SM (November 2013). "Small molecules activating TrkB receptor for treating a variety of CNS disorders". CNS Neurol Disord Drug Targets. 12 (7): 1066–77. doi:10.2174/18715273113129990089. PMID 23844685. 
  54. ^ Zhang JC, Yao W, Hashimoto K (2016). "Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets". Curr Neuropharmacol. 14 (7): 721–31. PMC 5050398Freely accessible. PMID 26786147. 
  55. ^ Liu C, Chan CB, Ye K (2016). "7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders". Transl Neurodegener. 5: 2. doi:10.1186/s40035-015-0048-7. PMC 4702337Freely accessible. PMID 26740873. 
  56. ^ Liu X, Chan CB, Jang SW, Pradoldej S, Huang J, He K, Phun LH, France S, Xiao G, Jia Y, Luo HR, Ye K (December 2010). "A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect". J. Med. Chem. 53 (23): 8274–86. doi:10.1021/jm101206p. PMC 3150605Freely accessible. PMID 21073191. 
  57. ^ Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K (October 2014). "Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation". Int. J. Neuropsychopharmacol. 18 (4). doi:10.1093/ijnp/pyu077. PMC 4360225Freely accessible. PMID 25628381. 
  58. ^ Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Han M, Hashimoto K (December 2015). "Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression". Psychopharmacology. 232 (23): 4325–35. doi:10.1007/s00213-015-4062-3. PMID 26337614. 
  59. ^ Chang HA, Wang YH, Tung CS, Yeh CB, Liu YP (September 2016). "7,8-Dihydroxyflavone, a Tropomyosin-Kinase Related Receptor B Agonist, Produces Fast-Onset Antidepressant-Like Effects in Rats Exposed to Chronic Mild Stress". Psychiatry Investig. 13 (5): 531–540. doi:10.4306/pi.2016.13.5.531. PMC 5067348Freely accessible. PMID 27757132. 
  60. ^ Zhang MW, Zhang SF, Li ZH, Han F (December 2016). "7,8-Dihydroxyflavone reverses the depressive symptoms in mouse chronic mild stress". Neurosci. Lett. 635: 33–38. doi:10.1016/j.neulet.2016.10.035. PMID 27773794. 
  61. ^ Zanos, Panos; Moaddel, Ruin; Morris, Patrick J.; Georgiou, Polymnia; Fischell, Jonathan; Elmer, Greg I.; Alkondon, Manickavasagom; Yuan, Peixiong; Pribut, Heather J.; Singh, Nagendra S.; Dossou, Katina S. S.; Fang, Yuhong; Huang, Xi-Ping; Mayo, Cheryl L.; Wainer, Irving W.; Albuquerque, Edson X.; Thompson, Scott M.; Thomas, Craig J.; Zarate Jr, Carlos A.; Gould, Todd D. (2016). "NMDAR inhibition-independent antidepressant actions of ketamine metabolites". Nature. 533: 481–486. doi:10.1038/nature17998. ISSN 0028-0836. PMC 4922311Freely accessible. PMID 27144355. 
  62. ^ NIH/National Institute of Mental Health. (2016, May 4). Ketamine lifts depression via a byproduct of its metabolism: Team finds rapid-acting, non-addicting agent in mouse study. ScienceDaily. Retrieved May 7, 2016
  63. ^ Rosenblat JD, McIntyre RS (2018). "Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials". J Affect Disord. 227: 219–225. doi:10.1016/j.jad.2017.10.042. PMID 29102836. 
  64. ^ Cohen IV, Makunts T, Atayee R, Abagyan R (2017). "Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications". Sci Rep. 7 (1): 1450. doi:10.1038/s41598-017-01590-x. PMC 5431207Freely accessible. PMID 28469132. 
  65. ^ Nagele P, Zorumski CF, Conway C (2018). "Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts". J Clin Psychopharmacol. doi:10.1097/JCP.0000000000000837. PMID 29360650. 
  66. ^ Zorumski CF, Nagele P, Mennerick S, Conway CR (2015). "Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy". Front Psychiatry. 6: 172. doi:10.3389/fpsyt.2015.00172. PMC 4673867Freely accessible. PMID 26696909. 
  67. ^ Harrison, Pam (April 7, 2016). "Parkinson's Drug Highly Effective for Resistant Depression". www.medscape.com. WebMD. Retrieved 2018-02-12. 
  68. ^ Chen C, Wang Z, Zhang Z, Liu X, Kang SS, Zhang Y, Ye K (January 2018). "The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease". Proc. Natl. Acad. Sci. U.S.A. 115 (3): 578–583. doi:10.1073/pnas.1718683115. PMID 29295929. 
  69. ^ "MIF-1 - AdisInsight". adisinsight.springer.com. Retrieved 23 Aug 2002. 

Further reading[edit]

  • Ionescu DF, Papakostas GI (2017). "Experimental medication treatment approaches for depression". Transl Psychiatry. 7 (3): e1068. doi:10.1038/tp.2017.33. PMID 28323287. 
  • Garay RP, Zarate CA, Charpeaud T, Citrome L, Correll CU, Hameg A, Llorca PM (2017). "Investigational drugs in recent clinical trials for treatment-resistant depression". Expert Rev Neurother. 17 (6): 593–609. doi:10.1080/14737175.2017.1283217. PMID 28092469. 
  • Dhir A (2017). "Investigational drugs for treating major depressive disorder". Expert Opin Investig Drugs. 26 (1): 9–24. doi:10.1080/13543784.2017.1267727. PMID 27960559. 

External links[edit]